P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)

Bibliographic Details
Published in:	HemaSphere
Main Authors:	J. Y. Chen, L. Johnson, K. M. McKenna, T. S. Choi, J. Duan, D. Feng, J. M. Tsai, N. Garcia-Martin, K. Sompalli, R. Maute, P. Vyas, R. Majeti, C. H. M. Takimoto, J. Liu, G. Ramsingh, M. P. Chao, J.-P. Volkmer, I. L. Weissman
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845844.10159.58

Similar Items

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
by: D. A. Sallman, et al.
Published: (2022-06-01)

PB1922: EFFECTIVENESS OF AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A RETROSPECTIVE COHORT STUDY OF 382 PATIENTS
by: N. Rajakumaraswamy, et al.
Published: (2022-06-01)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
by: Lisa Johnson, et al.
Published: (2023-08-01)

P550: A PHASE 3, RANDOMIZED TRIAL OF MAGROLIMAB IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH ACUTE MYELOID LEUKEMIA INELIGIBLE FOR INTENSIVE CHEMOTHERAPY (ENHANCE-3)
by: N. G. Daver, et al.
Published: (2022-06-01)

P774: CLINICAL OUTCOMES ASSOCIATED WITH AZACITIDINE MONOTHERAPY FOR TREATMENT-NAIVE PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS): A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
by: K. Hasegawa, et al.
Published: (2022-06-01)

P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA
by: N. G. Daver, et al.
Published: (2022-06-01)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
by: A. DeZern, et al.
Published: (2022-06-01)

Cost-effectiveness of azacitidine compared with low-doses of chemotherapy (LDC) in myelodysplastic syndrome (MDS)
by: Myrna Candelaria-Hernández, et al.
Published: (2017-06-01)

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine
by: Daisuke Okamura, et al.
Published: (2014-01-01)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
by: Amer M. Zeidan, et al.
Published: (2023-08-01)

S132: TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS
by: N. G. Daver, et al.
Published: (2022-06-01)

MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
by: Massimo Breccia, et al.
Published: (2012-02-01)

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system
by: Thomas Prebet, et al.
Published: (2016-10-01)

RELAPSED UBTF-TD MDS TREATED WITH VENETOCLAX AND AZACITIDINE
by: Henrik Hasle, et al.
Published: (2023-12-01)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs
by: Julie A. I. Thoms, et al.
Published: (2025-05-01)

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
by: Stefanie Jilg, et al.
Published: (2019-04-01)

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS
by: Amy E. DeZern, et al.
Published: (2025-08-01)

Targeting CD47/SIRPα in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Preclinical and Clinical Developments of Magrolimab
by: Fadi Haddad, et al.
Published: (2021-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
by: R Edlin, et al.
Published: (2010-05-01)

P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA
by: P. Vyas, et al.
Published: (2022-06-01)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE
by: I. Mandac Smoljanovic, et al.
Published: (2024-01-01)

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
by: Xuefeng Li, et al.
Published: (2025-05-01)

Survival of myelodysplastic syndrome patients after azacitidine therapy
by: Kanticha Thammagul, et al.
Published: (2026-04-01)

Cytogenetic study of Brazilian patients with myelodysplastic syndrome (MDS)
by: Tamara Borgonovo, et al.
Published: (2005-12-01)

Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome
by: Jorge E. Cortes, et al.
Published: (2025-10-01)

“Low‐risk” myelodysplastic neoplasm (MDS): Time for a name change?
by: Shoshana Burke, et al.
Published: (2025-01-01)

Effect of 5-Azacitidine Treatment on Redox Status and Inflammatory Condition in MDS Patients
by: Paola Montes, et al.
Published: (2022-01-01)

Integrated genetic, epigenetic, and immune landscape of mutant AML and higher risk MDS treated with azacitidine
by: Amer M. Zeidan, et al.
Published: (2024-06-01)

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine
by: Francesca Tiso, et al.
Published: (2025-01-01)

Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS)
by: Josephine Lucero, et al.
Published: (2023-06-01)

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape
by: Daniel Karel, et al.
Published: (2024-04-01)

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes
by: Ashwin Unnikrishnan, et al.
Published: (2017-07-01)

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
by: Gareth P. Gregory, et al.
Published: (2019-04-01)

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine
by: Theodoros Karantanos, et al.
Published: (2022-12-01)

Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
by: Gabriel N. Mannis, et al.
Published: (2025-06-01)

Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
by: Cristina A. Tentori, et al.
Published: (2024-05-01)

Restoration of Autophagy and Apoptosis in Myelodysplastic Syndromes: The Effect of Azacitidine in Disease Pathogenesis
by: Georgia Tsekoura, et al.
Published: (2025-07-01)

Impact of Skeletal Muscle Depletion on Patients with Myelodysplastic Syndrome Treated with Azacitidine
by: Eri Takada, et al.
Published: (2024-02-01)